SNMMI-led criteria back FET PET for glioma; Bracco announces FDA-cleared aneurysm AI; Cu-64 PSMA agent gets breakthrough designation

Listen to this post
read by AI voices · all episodesA workgroup convened by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) rated F-18 floretyrosine (FET) PET appropriate for glioma biopsy planning and for separating tumor from treatment-related changes.
Bracco and Avicenna.AI announced Food and Drug Administration (FDA) clearance of brain aneurysm detection software, Clarity Pharmaceuticals reported a breakthrough designation for a PSMA PET agent, the American Cancer Society tied prostate biopsy decisions to MRI, and the FDA posted an Arrow guidewire alert.
- Guidelines Nov 12, 2026A 16-member workgroup convened by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), with members representing SNMMI, the American Society of Neuroradiology and the Society for Neuro-Oncology, published appropriate use criteria for F-18 floretyrosine (FET) PET in primary brain tumors in the Journal of Nuclear Medicine on Nov. 12. Biopsy planning in suspected glioma (score 7) and differentiation of viable tumor from treatment-related changes in adult-type diffuse glioma (score 8) were rated appropriate, and no scenario was rated rarely appropriate. The criteria follow the FDA approval of F-18 floretyrosine (Pixclara, Telix) in September, AuntMinnie reported.Sources: Journal of Nuclear Medicine, AuntMinnie
- AI Nov 13, 2026Bracco and Avicenna.AI said Uptunity Aneurysm received Food and Drug Administration (FDA) 510(k) clearance as a concurrent reading aid that detects and assesses brain aneurysms on cerebral CT angiography, identifying suspected saccular aneurysms larger than 3 mm. For known aneurysms, a follow-up function gives quantitative measurements and comparisons between exams, according to AuntMinnie. It is the first product in Bracco's Uptunity portfolio of interpretive AI software; the report gave no clearance date and no accuracy or reader-study data.Source: AuntMinnie
- AI Nov 12, 2026Naitive Technologies received Food and Drug Administration (FDA) 510(k) clearance for OsteoSight Spine, software that analyzes routine lumbar spine, thoracic spine and chest X-rays taken for other clinical concerns in patients 50 and older to identify those at risk for low bone mineral density, the company said Nov. 12. It provides a report to aid the interpreting physician, according to the company, which said it develops AI-driven software. The clearance follows the FDA's September 2025 clearance of OsteoSight for hip and pelvis X-rays. Neither the company release nor OrthoWorld reported performance data.Sources: Naitive Technologies, OrthoWorld
- FDA Nov 12, 2026Clarity Pharmaceuticals said the Food and Drug Administration (FDA) granted 64Cu-SAR-bisPSMA breakthrough therapy designation for PET of PSMA-positive lesions in men with suspected prostate cancer recurrence based on elevated PSA, which the company called the first such designation in PSMA PET imaging. In the investigator-initiated Co-PSMA study cited by the company, 78% (39/50) of participants were positive on next-day 64Cu-SAR-bisPSMA PET/CT versus 36% (18/50) on 68Ga-PSMA-11 PET/CT. Topline data from the pivotal AMPLIFY and CLARIFY trials are expected in the first half of 2027, the company said.
- Guidelines Nov 12, 2026The American Cancer Society (ACS) guideline, published Nov. 12 in CA: A Cancer Journal for Clinicians, says men with a confirmed elevated PSA should be offered MRI and/or a validated biomarker to guide biopsy decisions. It defines an elevated PSA as 3.0 ng/mL or higher for men aged 45 to 69 and recommends PSA-based screening every two years for average-risk men aged 50 to 69, the ACS said.
- FDA Nov 10, 2026The Food and Drug Administration (FDA) posted an early alert on Nov. 10 on Arrow International's removal of products with spring wire guide components, including hydrophilic-coated guidewires and pressure-injectable peripherally inserted central catheters. The coating may swell inconsistently when hydrated with saline and clump, and detachment could release particles into the bloodstream, the FDA said. Arrow reported no serious injuries or deaths and told customers to stop using and quarantine affected product.Sources: FDA, FDA recalls list
The weekly innovation roundup for radiology, published every Sunday for the week before; every item links to its sources. Latest radiology news · All specialties